Elasto-FibroTest 1 is the first diagnostic test for the liver that combines the results of the FibroTest-ActiTest with an elastography result, directly from your smartphone.
Launch of the HCV-GenoFibroTest 2 , which anticipates the response to interferon treatments for hepatitis C; in particular in combination with FibroTest and genotype IL28b.
FibroMax offers a complete diagnosis of the state of the liver with a single blood test:
FibroTest becomes available in the United States, distributed by LabCorp, under the FibroSure brand.
A few years later, BioPredictive tests were distributed by the major North American laboratories.
Founding of BioPredictive, head of R&D, business development and distribution of FibroTest-ActiTest
FibroTest 6 developed by the Hepatology Department team at La Pitié-Salpêtrière University Hospital, Paris, France. The first combination of blood markers that replaces liver biopsies when testing for hepatic fibrosis. Patents held by the Assistance Publique des Hôpitaux de Paris (APHP).
METAVIR 7 classification, which separates fibrosis and activity in the histological evaluation (the biopsy) of the seriousness of the liver disease.
The first test 8 for hepatic fibrosis combining the usual blood markers.
Innovation is part of BioPredictive's DNA.
This has been part of the company's routine since 2002:
Quality at all costs is a core priority of BioPredictive: as a technology that has been validated by over 300 clinical trials FibroTest is an approved way of diagnosing the four most common liver diseases, including specific populations including : HIV co-infected 21 , transplanted patients 22 23 , vasculitis 24 , haemophilia 25 or primary biliary cirrhosis 26 but also for a large age spectrum, from children 27 to elderly patients 28 .
Quality and safety: BioPredictive's algorithms offer reliable diagnostic tools that give robust and reproducible results with an applicability of nearly 100% 29 .
Patients are at the heart of BioPredictive's concerns, and they are systematically taken into account throughout our work and our approach.
In 2002, we modernized the traditional results sheet to make it a reference document that would open up a genuine dialogue between patients and their physicians.
Finally, we aim to offer new tools, both to support users more effectively and to assist patients in the interpretation of their results.